Search results for "Thrombosis and Hemostasis"

showing 6 items of 6 documents

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies

2018

The complement and coagulation cascades interact at multiple levels in thrombosis and inflammatory diseases. In venous thrombosis, complement factor 3 (C3) is crucial for platelet and tissue factor (TF) procoagulant activation dependent on protein disulfide isomerase (PDI). Furthermore, C5 selectively contributes to the exposure of leukocyte procoagulant phosphatidylserine (PS), which is a prerequisite for rapid activation of monocyte TF and fibrin formation in thrombosis. Here, we show that monoclonal cofactor-independent antiphospholipid antibodies (aPLs) rapidly activate TF on myelomonocytic cells. TF activation is blocked by PDI inhibitor and an anti-TF antibody interfering with PDI bin…

inorganic chemicals0301 basic medicineComplement factor I030204 cardiovascular system & hematologyMonocytesImmunoglobulin GThromboplastinThrombosis and HemostasisMice03 medical and health sciencesTissue factor0302 clinical medicineimmune system diseasesmedicineAnimalsPlateletneoplasmsBlood CoagulationMice KnockoutVenous ThrombosisComplement component 5biologyChemistryMonocyteComplement C5Complement C3Hematologynervous system diseasesbody regions030104 developmental biologymedicine.anatomical_structureCoagulationAntibodies Antiphospholipidbiology.proteinCancer researchAntibodyBlood Advances
researchProduct

Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling.

2018

The tissue factor (TF) pathway serves both hemostasis and cell signaling, but how cells control these divergent functions of TF remains incompletely understood. TF is the receptor and scaffold of coagulation proteases cleaving protease-activated receptor 2 (PAR2) that plays pivotal roles in angiogenesis and tumor development. Here we demonstrate that coagulation factor VIIa (FVIIa) elicits TF cytoplasmic domain-dependent proangiogenic cell signaling independent of the alternative PAR2 activator matriptase. We identify a Lys-Gly-Glu (KGE) integrin-binding motif in the FVIIa protease domain that is required for association of the TF-FVIIa complex with the active conformer of integrin β1. A po…

0301 basic medicineCell signalingImmunologyIntegrinNeovascularization PhysiologicFactor VIIa030204 cardiovascular system & hematologyBiochemistryThromboplastinThrombosis and Hemostasis03 medical and health sciencesTissue factorMice0302 clinical medicineAnimalsHumansReceptor PAR-2Protein Interaction Domains and MotifsProtein Interaction MapsProtein kinase ACells CulturedIntegrin bindingBinding SitesbiologyChemistryIntegrin beta1Cell BiologyHematologyCell biologyCrosstalk (biology)030104 developmental biologyADP-Ribosylation Factor 6biology.proteinNIH 3T3 CellsPhosphorylationSignal transductionProtein BindingSignal TransductionBlood
researchProduct

Macrophage protease-activated receptor 2 regulates fetal liver erythropoiesis in mice.

2020

AbstractDeficiencies in many coagulation factors and protease-activated receptors (PARs) affect embryonic development. We describe a defect in definitive erythropoiesis in PAR2-deficient mice. Embryonic PAR2 deficiency increases embryonic death associated with variably severe anemia in comparison with PAR2-expressing embryos. PAR2-deficient fetal livers display reduced macrophage densities, erythroblastic island areas, and messenger RNA expression levels of markers for erythropoiesis and macrophages. Coagulation factor synthesis in the liver coincides with expanding fetal liver hematopoiesis during midgestation, and embryonic factor VII (FVII) deficiency impairs liver macrophage development…

0301 basic medicinemedicine.medical_specialtyBiologyThrombosis and Hemostasis03 medical and health sciencesMice0302 clinical medicineHepcidinInternal medicinemedicineMacrophageAnimalsReceptor PAR-2ErythropoiesisProtease-activated receptor 2Mice KnockoutFetusMacrophagesHematologymedicine.diseaseHemolysisHaematopoiesis030104 developmental biologyEndocrinologymedicine.anatomical_structureLiver030220 oncology & carcinogenesisbiology.proteinErythropoiesisBone marrowBlood advances
researchProduct

A targeted proteomics investigation of the obesity paradox in venous thromboembolism

2021

Abstract The obesity paradox, the controversial finding that obesity promotes disease development but protects against sequelae in patients, has been observed in venous thromboembolism (VTE). The aim of this investigation was to identify a body mass–related proteomic signature in VTE patients and to evaluate whether this signature mediates the obesity paradox in VTE patients. Data from the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism Project, a prospective cohort study of 693 VTE patients, were analyzed. A combined end point of recurrent VTE or all-cause death was used. Relative quantification of 444 proteins was performed using high-throughput targeted proteomics technolo…

0301 basic medicineOncologyProteomicsmedicine.medical_specialtyDisease030204 cardiovascular system & hematologyThrombosis and Hemostasis03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLectins C-Typecardiovascular diseasesObesityProspective StudiesReceptors ImmunologicProspective cohort studyGenotypingMembrane Glycoproteinsbusiness.industryLeptinHazard ratioHematologyVenous Thromboembolismmedicine.diseaseObesityConfidence interval030104 developmental biologyMatrix Metalloproteinase 2businessObesity paradox
researchProduct

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

2019

Abstract Patients with isolated pulmonary embolism (PE) have a distinct clinical profile from those with deep vein thrombosis (DVT)-associated PE, with more pulmonary conditions and atherosclerosis. These findings suggest a distinct molecular pathophysiology and the potential involvement of alternative pathways in isolated PE. To test this hypothesis, data from 532 individuals from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism Project, a multicenter prospective cohort study with extensive biobanking, were analyzed. Targeted, high-throughput proteomics, machine learning, and bioinformatic methods were applied to contrast the acute-phase plasma proteomes of isolated PE pa…

MaleProteomeDatasets as TopicComorbidity030204 cardiovascular system & hematologyProteomicsBioinformaticsBiochemistryThrombosis and HemostasisMachine LearningPathogenesis0302 clinical medicineProtein-Arginine Deiminase Type 2Prospective StudiesProtein Interaction MapsProspective cohort study0303 health scienceseducation.field_of_studyVenous ThromboembolismHematologyMiddle AgedThrombosisPhenotypePulmonary embolismProteomeN-AcetylgalactosaminyltransferasesFemaleAdultQuantitative Trait LociImmunologyPopulationInterferon-gamma03 medical and health sciencesInterleukin-15 Receptor alpha SubunitmedicineHumansGlial Cell Line-Derived Neurotrophic FactoreducationAged030304 developmental biologybusiness.industryPulmonary SurfactantsCell BiologyAtherosclerosismedicine.diseaseOxidative StressGene Expression RegulationPulmonary EmbolismTranscriptomebusinessAcute-Phase ProteinsFollow-Up StudiesBlood
researchProduct

Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.

2021

Anti-A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS13) autoantibodies cause a severe ADAMTS13 deficiency in immune-mediated thrombotic thrombocytopenic purpura (iTTP). ADAMTS13 consists of a metalloprotease (M), a disintegrin-like (D) domain, 8 thrombospondin type 1 repeats (T1-T8), a cysteine-rich (C), a spacer (S), and 2 CUB domains (CUB1-2). We recently developed a high-throughput epitope mapping assay based on small, nonoverlapping ADAMTS13 fragments (M, DT, CS, T2-T5, T6-T8, CUB1-2). With this assay, we performed a comprehensive epitope mapping using 131 acute-phase samples and for the first time a large group of remission samples (n = 50). Ne…

MetalloproteinaseThrombospondinPurpura Thrombocytopenic IdiopathicbiologyPurpura Thrombotic Thrombocytopenicbusiness.industryThrombotic thrombocytopenic purpuraAutoantibodyHematologymedicine.diseaseADAMTS13Thrombosis and HemostasisCohort StudiesThrombospondin 1Epitope mappingImmune systemImmunologymedicineDisintegrinbiology.proteinHumansbusinessAgedAutoantibodiesBlood advances
researchProduct